Long‐term real‐life glycaemic outcomes with a hybrid closed‐loop system compared with sensor‐augmented pump therapy in patients with type 1 diabetes
- 2 December 2019
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 22 (4) , 583-589
Abstract
Aim: To compare glycaemic metrics at 3 and 6 months in patients with type 1 diabetes on a 670G hybrid closed‐loop (HCL) system after using a sensor‐augmented pump (SAP) for at least 3 months. Materials and Methods: A retrospective study from a centre that has the largest number of 670G users in the United States was conducted. Data from 202 SAP users were reviewed. Sixty‐one patients were excluded (two for steroid use, four for pregnancy, 27 for previous Enlite use, and 28 for non‐continuous use of 670G). Out of 141 patients who met the inclusion criteria, 127 (aged 21–68 years) had complete data. Results: HbA1c levels decreased by 0.4% at 3 months and were maintained at 6 months (7.6 ± 0.07 vs. 7.2 ± 0.08, P < 0.001) with no weight gain at 6 months. Time‐in‐range (70–180 mg/dL) increased from 59.5% ± 1.1% to 70.2% ± 1.2% and 70.1% ± 1.1% at 3 and 6 months ( P < 0.001), respectively. At 6 months, time spent in hypoglycaemia (180 mg/dL) were reduced by 30% (2.2% ± 0.2% vs. 3.2% ± 0.2%; P < 0.05) and 26% (28.3% ± 1.2% vs. 38.1% ± 1.2%; P < 0.001), respectively. More time in auto‐mode was associated with improved continuous glucose monitoring metrics, lower HbA1c and decreased glycaemic variability. Time in auto‐mode declined in men after 3 months, while women maintained similar auto‐mode use throughout the study. Conclusions: The HCL system improved HbA1c levels and time‐in‐range, and decreased time spent in hypoglycaemia and hyperglycaemia at 6 months. Auto‐mode use was significantly correlated with continuous glucose monitoring metrics and glycaemic outcomes.Keywords
Funding Information
- NIDDK (5T32DK063687‐14)
This publication has 21 references indexed in Scilit:
- Integrated Insulin Pump and Continuous Glucose Monitoring Technology in Diabetes Care Today: A Perspective of Real-Life Experience With the Minimed™ 670G Hybrid Closed-Loop SystemEndocrine Practice, 2018
- The Minimed™ 670G Hybrid Automated Insulin Delivery System: Setting The Right ExpectationsEndocrine Practice, 2018
- Beyond HbA1c: Comparing Glycemic Variability and Glycemic Indices in Predicting Hypoglycemia in Type 1 and Type 2 DiabetesDiabetes Technology & Therapeutics, 2018
- Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G SystemDiabetes Care, 2018
- Review of a Commercially Available Hybrid closed-loop insulin-delivery System in the Treatment of Type 1 DiabetesTherapeutic Delivery, 2017
- International Consensus on Use of Continuous Glucose MonitoringDiabetes Care, 2017
- Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 DiabetesDiabetes Technology & Therapeutics, 2017
- Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 DiabetesJAMA, 2016
- Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic RegistryDiabetes Care, 2015
- Regression toward the mean – a detection method for unknown population mean based on Mee and Chua's algorithmBMC Medical Research Methodology, 2008